MedCAC

AcronymDefinition
MedCACMedicare Evidence Development and Coverage Advisory Committee
References in periodicals archive ?
"Scientific Expertise and the Balance of Political Interests: MEDCAC and Medicare Coverage Decisions." Journal of Public Administration Research and Theory 22 (1): 55-81.
Most of the MEDCAC advisers said that they were not satisfied by the Medicare-population data in the National Lung Screening Trial (NLST).
MedCAC is an advisory committee that reviews and evaluates medical and scientific literature and TAs, examines additional data and information on the effectiveness and appropriateness of items and services under review, and provides independent guidance and expert advice.
(7.) Dr Aubry is Senior Clinical and Policy Advisor for the Center for Medical Technology Policy (CMTP), was twice a member of the Center for Medicare and Medicaid Services (CMS) Medicare Coverage and Advisory Committee (MedCAC) and former Chair of the Blue Cross Blue Shield Association Technology Evaluation Committee (BCBSA TEC) Medical Advisory Panel.
To examine whether the data used by MedCAC was generalizable to the Medicare population, Mr.
The independent panel, now called the Medicare Evidence Development and Coverage Advisory Committee (MedCAC), reviews the literature described in a technology assessment and votes on the evidence to determine the health benefit of the medical procedure or device, wrote Sanket S.
Faced with this problematic situation, CMS asked the Medicare Evidence Development & Coverage Advisory Committee (MedCAC)--formerly MCAC--whether it could carve a path to HDE coverage through its clinical trial policy.
Members of MEDCAC (the Medicare Evidence Development and.
The proposal followed a Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting in which a majority of committee members expressed moderate confidence in the technology's ability to determine with adequate specificity and sensitivity the presence of polyps greater than 10 mm, but less confidence in detecting smaller polyps.
Medtronic plc, a global leader in heart valve therapies, will deliver public comment during the Centers for Medicare & Medicaid Services (CMS) Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting on July 25, which will assess whether scientific evidence supports requiring hospitals and heart team members to meet pre-specified volume requirements for TAVR programs.
Following the MedCAC meeting and a subsequent meeting with the CMS, Dendreon committed to collecting additional data in the registry.